BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/29/2024 8:40:08 AM | Browse: 89 | Download: 408
 |
Received |
|
2024-08-27 08:40 |
|
Peer-Review Started |
|
2024-09-05 02:15 |
|
First Decision by Editorial Office Director |
|
2024-10-11 03:37 |
|
Return for Revision |
|
2024-10-11 03:37 |
|
Revised |
|
2024-10-24 17:10 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-11-12 02:36 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-11-12 06:28 |
|
Articles in Press |
|
2024-11-12 06:28 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-11-15 00:54 |
|
Publish the Manuscript Online |
|
2024-11-29 08:40 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Anmol Singh, Aalam Sohal and Akash Batta |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Akash Batta, Assistant Professor, MD, Department of Cardiology, Dayanand Medical College and Hospital, Tagore Nagar, Civil Lines, Ludhiana 141001, Punjab, India. akashbatta02@gmail.com |
| Key Words |
Glucagon-like peptide-1 receptor agonists; Metabolic dysfunction-associated steatotic liver disease; Metabolic dysfunction-associated steatohepatitis; Liver fibrosis; Semaglutide; Tirzepatide; Survodutide |
| Core Tip |
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 1/3rd of the global population, leading to significant morbidity and mortality. GLP-1 agonists may decrease the risk of progression of MASLD by reducing fatty acid oxidation and cytokine production. GLP-1/GIP receptor agonists (RA) (tirzepatide) and Glucagon/GLP-1 RA (survodutide, efinopegdutide and pemvidutide), have also shown promising results in resolving metabolic dysfunction-associated steatohepatitis (MASH) and demonstrating histological improvement in liver fibrosis. The advancing field of MASH management points to a promising future, with combination therapies likely to significantly improve patient outcomes. |
| Publish Date |
2024-11-29 08:40 |
| Citation |
Singh A, Sohal A, Batta A. GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis. World J Gastroenterol 2024; 30(48): 5205-5211 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i48/5205.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i48.5205 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
